PROCEPT's Install-Base Reset: The AQUABEAM-to-HYDROS Pivot
Procedures missed on legacy accounts, but replacements, pricing, and DTC are the new levers — can they restore the growth narrative?
PRCT · Earnings Call · 2026-08-04
A story of two installed bases
PROCEPT BioRobotics reported Q2 2026 revenue of $94.5M, up 19% YoY, and U.S. procedures grew 21% — but that growth fell short of expectations. The culprit, as CEO Larry Wood put it bluntly, was the legacy fleet:
The contrast between the performance of HYDROS and AQUABEAM accounts has also made the opportunity in our existing installed base increasingly clear. We are, therefore, accelerating our efforts to upgrade legacy AQUABEAM systems to HYDROS.
The AQUABEAM accounts are the oldest cohort, and they are now showing a distinct utilization deficit. Management attributes this to a combination of an older platform, a preferential shift of surgeons to the newer HYDROS system, and perhaps a bit of commercial focus. Whatever the cause, the company's response is a deliberate replacement cycle — 14 replacement systems were sold in Q2 alone, and management now expects roughly 40 for the full year, with an ASP between $300k and $325k. Larry Wood noted that replacements "will remain an important part of our commercial strategy" and should "flip utilization over time" as legacy systems are retired. This marks a clear strategic pivot: the company is no longer just selling to new greenfield accounts; it is converting its own installed base to the higher-performing platform. Investors should watch whether this replacement pull-forward cannibalizes greenfield demand or meaningfully lifts procedure productivity, a key question for the 2027 outlook.
Pricing power and a path to profitability
Even as procedures disappointed, the company demonstrated pricing discipline. U.S. HYDROS system ASP reached approximately $495k in Q2, up from $485k in Q1 and $435k for full-year 2025. Management is guiding second-half ASP to $480k–$490k, which, when blended with replacement economics, implies a system revenue range of $115M–$122M. Gross margin expanded to 66% in Q2, helped by a $2.9M tariff recovery — a theme echoed across many other recent_earnings_reporters. On the bottom line, the company reiterated positive adjusted EBITDA for Q4 and narrowed OpEx guidance to $355M–$360M, a disciplined increase tied to DTC investments. As CFO Kevin Waters explained, "we looked at other areas in the organization where perhaps we don't need to spend as much" to fund the new patient-activation push. “We're going to do this very thoughtfully.” — Kevin Waters, Chief Financial Officer · 2026-08-04 The gross margin story is also visible in the fundamentals: Gross Margin has climbed from 61% in 2020 to 65% in the latest quarter, and the trend is likely to continue as HYDROS mix increases and operating leverage kicks in.
Patient activation: a new growth lever
The company is pivoting from a pure physician-facing sales model to one that includes direct-to-consumer outreach. Active pilots are now running in 18 U.S. markets, using television, radio, digital, and social. Early leading indicators — increased website traffic, stronger digital engagement, and more interaction with patient education resources — are encouraging, but management cautions that it takes months to convert interest into procedures. Larry Wood stated, "it's a no-regrets move to activate these patients," while Kevin Waters emphasized the trade-off: "This is a game of trade-offs. It's not incremental spend on the business." Historically, PROCEPT has been procedure-focused, but as Larry noted in the prior call, "there's just so much basic work that can be done quickly." The shift to patient activation is a strategic departure that could unlock a much larger addressable pool of men with BPH currently on the sidelines. If the pilot data proves positive, this could be a durable growth driver beyond the immediate upgrade cycle.
Confluence and differentiation
PROCEPT's tariff recovery is part of a broader market theme — many recent reporters, including AAPL and BAX, booked similar refunds. But the AQUABEAM-to-HYDROS replacement strategy is company-specific. The stock has been crushed, down ~78% from its December 2024 peak, with the recent 90-day tape still in decline. Yet management is projecting Q4 EBITDA positivity for the first time. The disconnect between the operational pivot and the share price suggests investors are waiting for tangible proof of procedure acceleration. As one analyst pressed, "Why are hospitals buying systems if utilization is coming down?" The answer given — that HYDROS accounts show markedly better per-system output — is the heart of the bull thesis. The key risk is whether the replacement program can move the needle fast enough and whether the DTC spend pays off without eroding margins. If the company hits its guided 54k–56k U.S. procedures and EBITDA-positive Q4, the narrative could turn. If not, the market may remain skeptical of the turnaround story.